期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 213, 期 10, 页码 2039-2048出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20150477
关键词
-
资金
- Cancer Council of Victoria ([Sydney Parker Smith Postdoctoral Research Fellowship])
- Leukemia Foundation National Research Program Clinical PhD Scholarship
- Lady Tata Postdoctoral Fellowship
- National Health and Medical Research Council [1016701, 1020363, APP1049720]
- Leukemia and Lymphoma Society (SCOR grant) [7001-13]
- estate of Anthony (Toni) Redstone OAM
- Melbourne International Research Scholarship (University of Melbourne)
- Melbourne International Fee Remission Scholarship (University of Melbourne)
- Australian Postgraduate Award
- Cancer Therapeutics CRC Top-up Scholarship
- Ian Potter Foundation
- Australian Government Independent Medical Research Institutes Infrastructure Support Scheme
- Victorian State Government Operational Infrastructure Support Program
Neoplastic transformation is driven by oncogenic lesions that facilitate unrestrained cell expansion and resistance to antiproliferative signals. These oncogenic DNA lesions, acquired through errors in DNA replication, gene recombination, or extrinsically imposed damage, are thought to activate multiple tumor suppressive pathways, particularly apoptotic cell death. DNA damage induces apoptosis through well-described p53-mediated induction of PUMA and NOXA. However, loss of both these mediators (even together with defects in p53-mediated induction of cell cycle arrest and cell senescence) does not recapitulate the tumor susceptibility observed in p53(-/-) mice. Thus, potentially oncogenic DNA lesions are likely to also trigger apoptosis through additional, p53-independent processes. We found that loss of the BH3-only protein BIM accelerated lymphoma development in p53-deficient mice. This process was negated by concomitant loss of RAG1/2-mediated antigen receptor gene rearrangement. This demonstrates that BIM is critical for the induction of apoptosis caused by potentially oncogenic DNA lesions elicited by RAG1/2-induced gene rearrangement. Furthermore, this highlights the role of a BIM-mediated tumor suppressor pathway that acts in parallel to the p53 pathway and remains active even in the absence of wild-type p53 function, suggesting this may be exploited in the treatment of p53-deficient cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据